New cream trio aims to outshine standard melasma treatment

NCT ID NCT07676994

Completed Disease control Sponsor: Ghurki Trust and Teaching Hospital Source: ClinicalTrials.gov ↗

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This study compares a new combination cream (containing isobutylamido-thiazolyl-resorcinol, retinoic acid, and dexamethasone) to the standard Kligman's formula for treating melasma, a common skin condition causing dark patches. The trial enrolls 56 women aged 16–60 who apply the cream nightly for three months. Researchers measure changes in melasma severity and quality of life at 4, 8, and 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: New trio combination (0.1% isobutylamido-thiazolyl-resorcinol, 0.1% retinoic acid, 0.1% dexamethasone)
What this could lead to: If effective, this cream could offer a new option for treating melasma with potentially fewer side effects than standard therapy.
What could go wrong: This is a small, early-phase trial with only 56 participants, so results may not apply to everyone. Possible side effects include redness and burning.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELASMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Melanosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELASMA

Contacts and locations

Locations

Ghurki Trust Teaching Hospital

Lahore, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.